Arbutus Biopharma Corp. Announces Board and Executive Changes

Ticker: ABUS · Form: 8-K · Filed: May 28, 2024 · CIK: 1447028

Arbutus Biopharma Corp 8-K Filing Summary
FieldDetail
CompanyArbutus Biopharma Corp (ABUS)
Form Type8-K
Filed DateMay 28, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: ABUS

TL;DR

Arbutus Biopharma (ABUS) board shake-up and exec comp changes filed. Watch for new direction.

AI Summary

Arbutus Biopharma Corp. announced on May 22, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. This 8-K filing also covers the submission of matters to a vote of security holders.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial stability.

Key Players & Entities

  • Arbutus Biopharma Corp. (company) — Registrant
  • May 22, 2024 (date) — Date of earliest event reported
  • TEKMIRA PHARMACEUTICALS Corp (company) — Former company name

FAQ

What specific changes were made to the board of directors?

The filing indicates the departure of certain directors and the election of new directors, though specific names are not detailed in the provided excerpt.

Were there any changes to Arbutus Biopharma's executive officers?

Yes, the filing mentions the departure of certain officers and updates to compensatory arrangements for certain officers.

What is the primary purpose of this 8-K filing?

The primary purpose is to report on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements, as well as the submission of matters to a vote of security holders.

When was the earliest event reported in this filing?

The earliest event reported was on May 22, 2024.

What was Arbutus Biopharma Corp.'s former name?

Arbutus Biopharma Corp. was formerly known as TEKMIRA PHARMACEUTICALS Corp.

Filing Stats: 932 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-05-28 16:25:02

Filing Documents

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. At the Meeting, the shareholders voted and: (1) elected each of the Company's nominees for director; (2) approved the Plan Amendment; (3) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular; and (4) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's shareholders at the Meeting. Proposal 1. To elect the seven director nominees named in the Proxy Statement/Circular each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Nominee Votes For Votes Withheld Broker Non-Votes Frank Torti, M.D. 116,514,685 6,089,738 24,915,140 Michael J. McElhaugh 110,465,378 12,139,045 24,915,140 Daniel Burgess 110,133,889 12,470,534 24,915,140 Richard C. Henriques 109,654,719 12,949,704 24,915,140 Keith Manchester, M.D. 105,954,077 16,650,346 24,915,140 James Meyers 110,186,534 12,417,889 24,915,140 Melissa V. Rewolinski, Ph.D. 111,055,063 11,549,360 24,915,140 Proposal 2. To approve an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,500,000 common shares: Votes For Votes Against Votes Abstained Broker Non-Votes 83,549,096 38,905,589 149,738 24,915,140 Proposal 3. To approve, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement/Circular: Votes For Votes Against Votes Abstained Broker Non-Votes 99,284,557 13,548,318 9,771,548 2

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended . 104 Cover page interactive data file (formatted as inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 28, 2024 ARBUTUS BIOPHARMA CORPORATION By: /s/ David C. Hastings Name: David C. Hastings Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.